A new once-in-a-day medication, Obicetrapib, has the attention of the medical within the international medical community since recent Phase 3 clinical trial results showed it had the potential to lower LDL ("bad") cholesterol and lipoprotein(a), both primary risk factors for heart attack and stroke. What makes this breakthrough. so special is its easy, once-a-day oral tablet form—a potential game-changer for millions who struggle to keep their cholesterol under control despite already being on aggressive treatment plans.

The breaththrough BROADWAY trial, conducted by Monash University's Victorian Heart Institute in Australia under the leadership of Professor Stephen Nicholls, recruited more than 2,500 patients with an age of approximately 65. They were either suffering from pre-existing cardiovascular disease or genetically elevated cholesterol levels and were already on the highest tolerable intensity of conventional cholesterol medications.

Members of the trial group were given either the experimental drug Obicetrapib or a placebo, in addition to their standard cholesterol-lowering treatments. In as little as 12 weeks, individuals taking Obicetrapib had a 32.6% reduction in LDL cholesterol and a 33.5% reduction in lipoprotein(a) (Lp[a])—a remarkable achievement, particularly given that Lp(a) has been notoriously resistant to treatment by conventional medicine.

In spite of the availability of statins and other lipid-lowering drug therapies, much of the patient population still cannot achieve guideline-recommended targets for LDL cholesterol and are thus at ongoing risk of heart attack and stroke.

LDL cholesterol can build up in blood vessels, forming plaques that narrow arteries and reduce blood flow—events that can lead to a heart attack or stroke. Lp(a), on the other hand, is an inherited protein that promotes blood clotting and arterial damage, with few if any effective treatments on the market.

"Such individuals, it appears, may not achieve their cholesterol levels low enough despite the optimal available therapies," explained Professor Nicholls. "Obicetrapib represents a promising new alternative—not only did it reduce LDL cholesterol by more than 30%, but we also witnessed a decrease in Lp(a), which is much more difficult to lower and is associated with elevated heart disease risk."

In contrast to many therapies that act on one type of lipid, Obicetrapib has the advantage of reducing both LDL and Lp(a)—a feat few drugs have managed to do. Having this dual effect in a single once-a-day oral tablet is an added convenience for already-complex medication regimens for patients.

Another noteworthy feature of the trial was how tolerable the drug was. Obicetrapib was widely welcomed by most participants, having no apprehending side effects or safety issues, based on the findings reported in The New England Journal of Medicine and presented during the European Atherosclerosis Society Congress in Glasgow.

Although Obicetrapib's impact in lowering LDL and Lp(a) is quite remarkable, the research didn't account for direct measures such as real reduction in heart attacks or strokes. Still, the relationship between lower LDL/Lp(a) and decreased cardiovascular risk has long been documented in medical research.

What this trial does, however, is offer strong evidence for a next-generation lipid-lowering therapy that could address the needs of patients who haven’t responded well to existing treatments. In clinical settings, even a 1% drop in LDL can translate to significant reductions in cardiovascular events over time.

Obicetrapib is being developed by NewAmsterdam Pharma, a Netherlands-based company. Although the BROADWAY trial has shown encouraging early findings, further studies on long-term endpoints—such as actual decreases in heart attacks, strokes, and cardiovascular mortality—are needed before regulatory bodies such as the FDA can grant approval for its broad use.

There's also the issue of how well Obicetrapib would work in individuals specifically chosen for high Lp(a), something this trial wasn't set up to test. Future research will explore these subpopulations more deeply.

Even so, authorities think the early indication is promising. "A valuable weapon in the war against heart disease," replied Nicholls. "It's easy to use, it works, and it could help bridge the gap for those who've exhausted their choices."

As cardiovascular disease continues to be the global leading cause of death, advances such as Obicetrapib could be the solution to confronting what is still a chronic global health problem. A once-a-day tablet that lowers both LDL and Lp(a) in a safe manner could transform primary and secondary prevention in cardiology, especially among high-risk patients already on multiple drugs.

Convenience and adherence are critical to the success of treatment, particularly in populations that are elderly or have multiple chronic diseases. A once-daily formulation ensures fewer side effects and increases the chances that patients will adhere to regimen compliance, leading to improved long-term outcomes.

As more research is conducted before Obicetrapib is an everyday addition to managing cholesterol, this experimental medication holds real potential. By successfully lowering two of the top heart disease villains in a single easy dose, it can potentially close a very important treatment gap for those most at risk.

August’s scorching weather has made even short trips outside exhausting and turned nights into sweaty, sleepless ordeals. With no air conditioning in many homes, people are using ice packs, wet towels, frozen water bottles and electric fans to cope. But a fan might not be doing you any favours; in fact, if you use it the wrong way, it could be raising your risk of a heart attack.

What the study says

A new study from the University of Sydney has found that while fans can make you feel blissful during a heatwave, they can also push your body into dangerous territory, particularly if you’re dehydrated. Researchers wanted to understand exactly how fans affect our bodies in hot and humid conditions, so they put 20 volunteers into a climate-controlled space set to 39.2 degrees Celsius with 49 per cent humidity.

The participants weren’t just asked to sit there and suffer. Scientists tracked their heart rate, core temperature, sweating, and comfort levels, both when they were properly hydrated and when they had been deliberately dehydrated (by avoiding fluids and water-rich foods for 24 hours). Each hydration state was tested twice — once with a fan blowing and once without.

Sweat, strain, and a shocking finding

The study revealed that using a fan while dehydrated increased sweat losses by around 60 per cent. Now, sweating might sound like a good thing when you’re overheating, but in this case, it pushed the body into a dangerous loop: more sweat loss means more dehydration, which means more cardiovascular strain. That extra strain can, in extreme cases, trigger heart attacks, particularly in vulnerable individuals.

Connor Graham, PhD, who led the study, explained that fans can help keep you cooler at temperatures up to around 39–40 degrees Celsius. But when the air gets hotter than your skin, the fan can actually heat your body faster than it can cool itself. Most extreme heat decedents do not have air conditioning but often own electric fans, he said. In hotter conditions, fans should be turned off, as they can worsen heat stress.

Why hydration is important

The study says that hydration is a game-changer. When the volunteers were well hydrated, fans were far less risky, even in the extreme heat chamber. But when hydration levels were low, the fan’s effects tipped from helpful to harmful, sending heart rate and body strain higher.

This is because sweat is our body’s primary cooling mechanism. When you’re hydrated, you can produce enough sweat to evaporate and take heat away from your body. But if you’re already running on empty, a fan simply accelerates fluid loss without actually cooling you enough. That’s like trying to run your car on fumes while flooring the accelerator.

Heatwaves, Britain, and fan habits

In the UK, people are not exactly built for this kind of weather. Their homes are designed to trap warmth, not keep it out, which is why fans are practically flying off the shelves in high street stores right now. But unlike in countries where air conditioning is the norm, we often rely on fans as our only cooling option and that’s where this warning matters.

It’s easy to assume that “more fan” means “more cool”. The reality is a bit more complicated. In moderately hot weather, a fan can help your sweat evaporate and keep you feeling comfortable. In extreme heat, particularly if your flat feels like a slow cooker, a fan can just push hot air onto your body, speeding up dehydration and heart strain.

How to use fans safely in a heatwave

Don’t chuck your fan in the bin just yet. Here are some science-backed ways to stay safe while keeping cool:

• Stay hydrated first — Drink water regularly throughout the day, not just when you feel thirsty. Herbal teas and diluted juices also count.
• Use fans strategically — Aim them across your body, not directly at your face, and combine them with open windows to improve airflow.
• Cool the room, not just yourself — Place a bowl of ice in front of the fan so it blows chilled air.
• Turn it off during extreme heat — If indoor temperatures are hotter than 40 degrees Celsius (or feel like it), skip the fan and switch to other cooling methods.
• Know your limits — Older adults, people with heart conditions, and those on certain medications are more vulnerable to heat strain.

Ottawa Public Health (OPH) is urging residents to monitor for symptoms of measles after confirming the city’s fifth case of the year. Officials say the individual, who has not been identified, likely contracted the virus while travelling in western Canada. While the risk to the general public remains low, OPH warns that certain people may have been exposed at specific locations around the city between August 5 and 8.

Potential Exposure Sites in Ottawa

In its Thursday alert, OPH listed several businesses and venues where possible exposure could have occurred:

• Shoppers Drug Mart, 702 Bank St., Aug. 5 from 9 p.m. to 11:30 p.m.
• Michaels, 165 Trainyards Dr., Aug. 5 from 8:15 p.m. to 10:30 p.m.
• Fitness Lab, 34 Beech St., Aug. 6 from 5:45 a.m. to 8:45 a.m.
• Wilf and Ada’s, 510 Bank St., Aug. 7 from 12:30 p.m. to 4 p.m.
• Izakaya Shingen, 201 Bank St., Aug. 8 from 5 p.m. to 8 p.m.
Cineplex Odeon, 2385 City Park Dr., Aug. 8 during the 6:50 p.m. screening of Fantastic Four: First Steps

Officials advise anyone who visited these locations during the listed times to watch for symptoms such as cough, fever, red eyes, and rash for 21 days after the possible exposure.

Exposure at Ottawa Hospital’s Emergency Department

The Ottawa Hospital has confirmed the same patient visited the General campus emergency department on August 11, waiting for several hours before being assessed in the early hours of August 12. Dr. Eric Eckbo, an infection control physician at the hospital, said measles was suspected during the examination. Infection control measures, including masking and isolation, were immediately implemented, and OPH was contacted.

Hospital staff are now following up with anyone who may have been exposed during that time, including immune-compromised individuals at higher risk of complications. Most people exposed will not develop measles due to immunity from vaccination or previous infection.

ALSO READ: Measles Death In Liverpool Highlights Vaccine Urgency For Children: Here's What Parents Need To know

Part of a Larger Outbreak

Ontario has been dealing with a significant measles outbreak this year, with 2,362 cases reported as of August 12, according to Public Health Ontario. Two of Ottawa’s five cases are linked to this provincial outbreak. Alberta is also experiencing a large number of cases, with dozens of new infections reported weekly.

No Local Transmission Detected

Despite these numbers, OPH says there is still no evidence of local measles transmission in Ottawa in 2025. Health officials credit this to high vaccination coverage in the community. However, they stress that measles remains one of the most contagious viruses and that the measles-containing vaccine is the most effective protection.

Advice for the Public

People who develop symptoms are urged to contact their primary healthcare provider before visiting any medical facility. If a hospital visit is necessary, they should wear a mask and inform staff immediately upon arrival. Those unable to get vaccinated, such as infants and people with compromised immune systems, are particularly vulnerable and should take extra precautions.

Canada eliminated measles in the 1990s due to strong vaccination programs, but declining immunization rates worldwide are fueling its return. Ottawa health officials are reminding residents that staying up to date on vaccinations remains the best way to prevent outbreaks.

From September, Eli Lilly will raise the UK price of its diabetes and weight-loss drug Mounjaro by as much as 170%. The US pharmaceutical giant says the increase will align UK costs with those in other developed nations and address “pricing disparities.”

The NHS will not be affected for now. The price surge is aimed at private patients and providers, who often negotiate discounts behind closed clinic doors. But for those paying out of pocket, the jump is steep, the highest monthly dose will soar from £122 to £330, while lower doses will rise by 45 to 138 per cent.

For many, this is more than a wallet shock. It could mean rethinking whether to continue treatment, especially since Mounjaro is often taken long term to maintain results. With so much at stake, here’s a closer look at what the drug does, who it’s for, and the benefits and risks to consider.

What is Mounjaro?

Mounjaro, the brand name for tirzepatide, is an injectable medication, notes Diabetes UK, and is approved in the UK for type 2 diabetes and, more recently, for obesity. It is part of a newer class of drugs that not only control blood sugar but also promote significant weight loss.

Unlike earlier medications such as Ozempic and Wegovy, both of which were based on semaglutide, Mounjaro works by activating two hormone receptors: GLP-1 and GIP, at the same time. This “dual agonist” approach appears to produce greater weight loss than single-receptor drugs.

How Does it Work?

Mounjaro increases levels of natural hormones called incretins. These hormones help the body release more insulin when needed, reduce glucose production by the liver, and slow digestion so you feel fuller for longer.

The result is a two-pronged effect:

Better blood sugar control in people with type 2 diabetes

Reduced appetite and calorie intake leading to weight loss

In clinical trials, people taking the highest dose (15 mg weekly) lost up to 21 per cent of their body weight. That’s on par with some bariatric surgeries, but without the invasive procedure.

Who Can Take Mounjaro?

For type 2 diabetes

Adults aged 18 and over who have not been able to control blood sugar with other medications, or who cannot tolerate them due to side effects or other conditions.

Typically prescribed if the person also has a BMI of 35 kg/m² or higher with obesity-related health issues, though exceptions exist for those with lower BMIs in certain ethnic groups or specific medical needs.

For obesity

In England and Wales: Recommended for people with a BMI of at least 35 kg/m² and related health conditions, including type 2 diabetes. Lower thresholds apply for some ethnic groups.

In Scotland: Available for people with a BMI of at least 30 kg/m² plus one obesity-related condition.

The Benefits

Significant weight loss that can improve or reverse obesity-related health problems

Improved blood sugar control in people with type 2 diabetes

Once-weekly dosing with a pre-filled pen for convenience

May reduce risk of complications from diabetes, though more research is ongoing for cardiovascular benefits

The Risks and Side Effects

Like other drugs in its class, Mounjaro can cause:

• Nausea, vomiting, diarrhoea, constipation, indigestion
• Risk of low blood sugar if taken with insulin or certain other diabetes drugs
• Possible risk of high blood sugar if insulin doses are cut too quickly
• In animal studies, an increased risk of thyroid tumors, whether this applies to humans is still unknown

Long-term safety data is limited since the drug is relatively new. Some people may also regain weight if they stop taking it.

Cost and Access Challenges

On the NHS, Mounjaro is free for those eligible under treatment guidelines, but rollout is gradual due to costs and support service limitations. Access for weight loss alone is prioritized for those with the highest clinical need.

Private prescriptions vary in cost and availability. After the September price hike, the financial burden will be significant for many patients, especially since ongoing treatment is often required to maintain benefits.

Life Without the Jab

If the higher cost puts Mounjaro out of reach, lifestyle changes can still deliver meaningful results. Strategies that mimic some of its effects include:

• Eating high-protein meals to promote satiety
• Choosing high-fibre foods to slow digestion
• Limiting ultra-processed foods that spike blood sugar
• Regular physical activity to improve insulin sensitivity